Chemoprevention Efficacy Study Nigeria - Trial NCT05979896
Access comprehensive clinical trial information for NCT05979896 through Pure Global AI's free database. This Phase 4 trial is sponsored by Malaria Consortium and is currently Recruiting. The study focuses on Malaria. Target enrollment is 800 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Malaria Consortium
Timeline & Enrollment
Phase 4
Jul 28, 2023
May 15, 2024
Primary Outcome
Chemoprevention failure as defined by qPCR positive parasites or malaria slide positive parasites,Prevalence of antimalarial resistance markers among chemoprevention failures (as defined in outcome 1),Drug concentrations of Sulfadoxine-pyrimethamine and amodiaquine among chemoprevention failures (as defined in outcome 1),Prevalence over time of parasites with dhfr/dhps/pfcrt/pfmdr1 mutations in symptomatic children with a positive diagnostic test residing in districts where SMC is implemented
Summary
The study aims to assess the chemoprevention efficacy of Sulfadoxine-Pyrimethamine and
 Amodiaquine (SPAQ) used in standard age-based dosing regimens used in Seasonal Malaria
 Chemoprevention (SMC) and SPAQ resistance marker prevalences and assocations among children 3
 - 59 months in Sokoto and Kwara States, Nigeria.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05979896
Non-Device Trial